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Abstract
Leber’s hereditary optic neuropathy is a neuro-ophthalmological entity characterized by acute or subacute 
bilateral, not simultaneous visual loss with centro cekal scotoma and occasional further visual improvement. 
This rare ophthalmological disease can be accompanied with dyschromatopsia. It is associated with a matri-
lineal inheritance pattern. Its diagnosis used to be solely clini¬cal, aided by imaging and neuro-physiological 
studies, until the advent of descriptions of mitochondrial biochemical abnormalities and genetic testing. We 
describe a case of 24 year old male with progressive painless deterioration of visual acuity and positive family 
history. © 2012 All rights reserved
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Introduction
Leber’s hereditary optic neuropathy is a neuro-
ophthalmological entity characterized by acute 
or subacute bilateral, not simultaneous visual 
loss with centro cekal scotoma and occasional 
further visual improvement. Th is rare ophthal-
mological disease can be accompanied with dys-
chromatopsia. It is associated with a matrilineal 
inheritance pattern. Its diagnosis used to be solely 
clinical, aided by imaging and neuro-physiolog-
ical studies, until the advent of descriptions of 
mitochondrial biochemical abnormalities and 
genetic testing. Primary point mutations occur 
at nucleotide positions 3460, 11778 and 14484 
of the mitochondrial genome coding for protein 
subunits of the respiratory chain complexes. Th e 
11778 mutation is most frequently observed, ac-
counting for 80-90% of described cases.2 Young 
males are primarily aff ected (80-90%), usu-
ally in their third decade of life. Females, carri-
ers of the disease, rarely express the symptoms.
Case report
A young man adult of 24 experienced a sudden 
progressive, painless decreasing of visual acuity of 
the right eye. Th e condition deteriorated over a few 
days. He also noticed that the colors when viewed 
with the right eye, were extremely pale. Th e left  
on the fi rst examination was with normal visual 
acuity. For 22 days visual acuity of the left  eye de-
creased. He had a healthy younger brother, with 
no visual disturbances. His mother remembered 
that his uncle (her brother) was 23 years old and 
had similar problem Th e patient did not smoke, 
nor did he consume any alcohol and was well 
nourished. He was not exposed to heavy metals.
At the time of the referral, two months aft er the 
onset of the disease, visual acuity was 0.01 in the 
right eye, and 0.1 in the left . During visual fi eld 
testing, centrocoecal scotoma on the right eye and 
central scotoma on the left  eye were found (Figure 
1). Subjectively present profound dyschromatop-
sia could not be objectively proved due to very low 
central vision. Pupillary responses were normal, 
and relative aff erent pupillary defect could not be 
detected. Th ere were no signs of intraocular in-
fl ammation and intraocular pressure was normal. 
Fundoscopic appearance was not impressive. Th e 
only thing that could be seen was slightly tortuous 
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papillary capillary network and very discrete dila-
tation and tortuosity of small peripapillary vessels, 
more pronounced on the right eye. On fl uorescein 
angiography, the vessels were intact, with no leak-
age (Figure 2). Pattern visual evoked potentials 
(VEP) were bilaterally almost extinct, with hardly 
discernible P100. Retrobulbar part of optic nerve 
showed no abnormalities on orbitalechography. 
Standard imaging studies (CT, MRI) excluded the 
presence of chiasmal or other intracranial mass le-
sion as well as foci of demy-
elinisation. Th e presence of 
sarcoidosis, tuberculosis and 
syphilis was also excluded 
with the appropriate serologi-
cal tests and chest radiogra-
phy. Peripheral blood sample 
was taken for mitochondrial 
DNA (mt DNA) isolation 
from leukocytes. A G11778A 
mutation was found in leuko-
cyte mtDNA and the muta-
tion was homoplasmic. Th is 
fi nding confi rmed earlier pre-
sumptive diagnose of LHON.
Follow-up showed no im-
provement of central visual 
acuity for almost a year, but 
thereaft er the left  eye vision 
started to improve. On the last 
check-up, 14 months aft er the 
onset of the disease, left  eye 
visual acuity recovered to 0.7 
but the right eye stayed at 0.1. 
On ophthalmoscopy, bilateral 
profound optic atrophy with 
empty, pale discs was found 
(Figure 3). On control pattern 
VEP there were no changes.
Th e mother`s leukocyte 
mt DNA has already been 
isolated and sent for analy-
sis. We hope to get consent 
from other family mem-
bers to perform studies on 
their mitochondrial genome.
During outpatient follow-
up, his symptoms have not 
increased or decreased, and 
he has been medicated using 
vitamin C (500 mg t. i. d.), vi-
tamin B1 (5 mg), vitamin B2 
(2 mg), vitamin B6 (2 mg), 
vitamin PP (20 mg), vitamin 
FIGURE 1.  Centrocoecal scotoma on the right eye and central scotoma on the left eye
FIGURE 2.  Intact vessels on fl uorescein angiography
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B5 (3 mg), in one tablet, t .i. d, and coenzyme 
Q10 (100 mg b .i .d.). Th e purpose of this supple-
mentation was to improve cellular ATP usage.
Discussion
Hereditary optic neuropathies are a group of dis-
eases with defi ned clinical presentation and diff er-
ent inheritance patterns. Th e clinical setting may 
be of acute, sub-acute or relentlessly progressive 
painless visual loss, bilateral (simultaneous or se-
quential), with centro cecal scotoma, altered color 
perception (dyschromatopsia) and optic atrophy. 
Th e inheritance pattern may present as autosomal 
dominant, recessive, X-linked or matrilineal (1).
In Leber’s hereditary optic neuropathy, male in-
dividuals in their teens or twenties suff er acute 
visual loss that is sequential in 78% of cases and 
simultaneous in 22% (2). Fundus examination 
in the initial stages shows papilledema and peri-
papillary microangiopathy, evolving to atrophy 
of the nerve fi ber layer of the retina and fi nally 
leading to optic atrophy and centrocecal sco-
toma (3). Family history is suggestive of mater-
nal inheritance in 50% of patients, and in the 
other 50% the disease seems to be sporadic (4).
Four main mutations of mitochondrial DNA 
(mtDNA) encompass over 90% of patients with 
Leber’s hereditary optic neuropathy: 11778 (genet-
ic subunit ND4), 14484 (ND6), 3460 (ND1) and 
14459 (ND6). Th e mutation at 14459 corresponds 
to the dystonia phenotype for Leber’s hereditary 
optic neuropathy (5). Mashima et al.6 assessed the 
prevalence of diff erent mutations in a sample of 80 
individuals with Leber’s hereditary optic neuropa-
thy and showed that 87% carried the mutation at 
11778, 9% at 14484 and 4% at 3460. Riordan-Eva 
et al. 2 found prevalence for the same mutations 
of respectively 75%, 15% and 8%. Oriental studies 
demonstrate higher proportions of 11778 muta-
tions than do Western studies (6,7). Biousse et al. 
(8) reported the 14484 mutation on monozygotic 
twins with distinct phenotypes (only one symp-
tomatic sibling), while genetic testing in the mother 
was negative, thereby suggesting de novo mutation.
Sadun et al. recently published that there is the 
strong infl uence of environmental risk factors, 
FIGURE 3.  Bilateral profound optic atrophy with empty, pale discs on ophthalmoscopy
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with smoking as the most common factor (9).
Multiple sclerosis (or MS-like disease) shares a 
rather uncommon comorbidity with Leber’s he-
reditary optic neuropathy. Some patients with Leb-
er’s hereditary optic neuropathy develop clinical 
features that are phenotypically indistinguishable 
from multiple sclerosis, and mutations for Leber’s 
neuropathy are considered to be a risk factor in 
the pathophysiology of multiple sclerosis (10,11).
On the other hand, prevalence studies among 
multiple sclerosis patients have failed to dem-
onstrate primary mtDNA mutations (12,13). It 
is currently recommended to proceed with mt 
DNA analysis for all young male multiple sclero-
sis patients with initial neuro-ophthalmological 
manifestations and peripapillary microangi-
opathy, especially those with bilateral symptoms 
and a positive family history for visual los (14).
Th ere is no specifi c treatment for Leber’s hereditary 
optic neuropathy. From an empirical standpoint, 
most if not all patients will receive an initial diag-
nosis of optic neuritis and will be treated, without 
any response, using steroid therapy at high doses. 
In a case-control study with patients carrying mu-
tations 14484, 3460 and 11778, combination thera-
py using idebenone / vitamin B2/vitamin C (which 
improves ATP availability) shortened the time re-
quired for vision recovery in the group using this 
therapy (11.1 months), in comparison with the 
placebo group (17.4 months; p = 0.03) (15). A sin-
gle-patient study backed by magnetic resonance 
spectroscopy of the central nervous system (31P-
MRS) showed clinical and imaging improvement
When idebenone treatment was instituted (ideben-
one is not available in Brazil, but only in Argentina: 
its action is similar to that of the coenzyme Q10) (16). 
Th e prognosis for vision recovery depends on 
the mutation reported. Good prognosis may be 
found in up to 50% of patients bearing the 14484 
mutation. Nevertheless, only 4% of patients with 
the 11778 mutation have gradual improvement, 
as we were able to observe in our patient (17).
Conclusion
A diagnosis of Leber’s hereditary optic neuropa-
thy should be suspected whenever young males 
develop bilateral visual loss, usually sequential, 
with a positive familial history. Neuro-ophthal-
mological examination may demonstrate sug-
gestive signs of Leber’s hereditary optic neu-
ropathy. Th e mutation at the 11778 locus is the 
most frequent mutation of mitochondrial DNA 
in Leber’s hereditary optic neuropathy patients.
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